VMD Sciences enabled access to an innovative therapy for a dog diagnosed with an inoperable soft tissue sarcoma, thereby illustrating the efficacy of regulatory pathways in veterinary medicine. After all local treatment options had been exhausted for a 10-year-old Tamaskan canine, a community veterinary oncologist requested assistance. VMD Sciences provided guidance throughout the regulatory process to import a medication approved in Taiwan, obtaining approval on January 22, 2025. This accomplishment expanded therapeutic options for the patient and underscored the substantial potential of Expanded Access Programs to enhance animal health worldwide.